Press Releases - Lifestyle Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity June 6, 2026
Press Releases - Lifestyle TEAMEX Delivers First EV-Drill LANCE in the United States to Pennsylvania Fire Department June 6, 2026
Press Releases - Lifestyle MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Stellantis N.V. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – STLA June 6, 2026
Press Releases - Lifestyle PureHealth Research Highlights Growing Consumer Interest in Lymphatic Wellness and Botanical Support June 6, 2026
Press Releases - Lifestyle Clinical Amino Acid Profiles Anchor PureHealth Research’s New Natural Peptides Supplements June 6, 2026
Press Releases - Lifestyle MONDAY INVESTOR DEADLINE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces – MEDP June 6, 2026
Press Releases - Lifestyle In HelloNation, Periodontics Expert Dr. Scott Kissel of Manhattan, NY, Details Why Microsurgical Techniques Matter in Periodontal Care June 6, 2026
Press Releases - Lifestyle AVAV INVESTOR NOTICE: AeroVironment, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces June 6, 2026
Press Releases - Lifestyle INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit June 6, 2026
Press Releases - Lifestyle People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data June 6, 2026
United Development Bank Receives FDIC Conditional Approval, Advances Formation of New Bellevue Community Bank 4 weeks ago